Evidence map›Paper›PMID 33570647›Full record

ArticleBlood advances2021

ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.

Nathan T Connell, Veronica H Flood, Romina Brignardello-Petersen, Rezan Abdul-Kadir, Alice Arapshian, Susie Couper, Jean M Grow, Peter Kouides, Michael Laffan, Michelle Lavin and 9 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05500807 (Emicizumab for Severe VON Willebrand Disease), which is not on this map. Cited by 180 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
180citing papers in PubMed, 9 pooled it
33.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05500807 phase1recruitingnot on this mapstarted 2022, after this paper: background citation

Emicizumab for Severe VON Willebrand Disease (VWD) and VWD/Hemophilia A

TypeinterventionalSponsorBleeding and Clotting Disorders Institute Peoria, IllinoisRan2022 to 2028Enrolled40ConditionsVon Willebrand Disease, Type 3, Concomitant VWD and HemophiliaArmsEmicizumab
3 · Its place in the literature

Who cites it

180 citing papers in PubMed, 9 syntheses or guidelines pooled it, 341 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. [Chinese guideline on the diagnosis and management of von Willebrand disease (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022
    Guideline
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Efficacy of Wilate Prophylaxis in Reducing Nosebleeds in Patients with Severe VWD - A Post-hoc Analysis of the WIL-31 Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Trial
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

120 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 16 institutions in 7 countries.

Nathan T ConnellHematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Veronica H FloodVersiti Blood Research Institute, Medical College of Wisconsin, Milwaukee, WI.
Romina Brignardello-PetersenDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Rezan Abdul-KadirDepartment of Obstetrics and Gynaecology and Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Foundation Hospital and Institute for Women's Health, University College London, London, United Kingdom.
Alice ArapshianMiddle Village, NY.
Susie CouperMaylands, WA, Australia.
Jean M GrowDepartment of Strategic Communication, Marquette University, Milwaukee, WI.
Peter KouidesMary M. Gooley Hemophilia Treatment Center, University of Rochester, Rochester, NY.
Michael LaffanCentre for Haematology, Imperial College London, London, United Kingdom.
Michelle LavinIrish Centre for Vascular Biology, Royal College of Surgeons in Ireland and National Coagulation Centre, St James's Hospital, Dublin, Ireland.
Frank W G LeebeekDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Sarah H O'BrienDivision of Hematology/Oncology, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH.
Margareth C OzeloHemocentro UNICAMP, University of Campinas, Campinas, Brazil.
Alberto TosettoHemophilia and Thrombosis Center, Hematology Department, S. Bortolo Hospital, Vicenza, Italy.
Angela C WeyandDepartment of Pediatrics, University of Michigan Medical School, Ann Arbor, MI.
Paula D JamesDepartment of Medicine, Queen's University, Kingston, ON, Canada; and.
Mohamad A KalotOutcomes and Implementation Research Unit, Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.
Nedaa HusainatOutcomes and Implementation Research Unit, Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.
Reem A MustafaOutcomes and Implementation Research Unit, Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.
University of Kansas Medical Center · USBrigham and Women's Hospital · USChildren’s Village · USErasmus MC · NLImpact · CAImperial College London · GBMarquette University · USMary M. Gooley Hemophilia Center · USMedical College of Wisconsin · USNationwide Children's Hospital · USOspedale San Bortolo · ITQueen's University · CARoyal College of Surgeons in Ireland · IEThe Royal Free Hospital · GBUniversidade Estadual de Campinas (UNICAMP) · BRUniversity of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundvon Willebrand disease (VWD) is a common inherited bleeding disorder. Significant variability exists in management options offered to patients.

objectiveThese evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of VWD.

methodsASH, ISTH, NHF, and WFH formed a multidisciplinary guideline panel. Three patient representatives were included. The panel was balanced to minimize potential bias from conflicts of interest. The University of Kansas Outcomes and Implementation Research Unit and the McMaster Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process, including performing and updating systematic evidence reviews (through November 2019). The panel prioritized clinical questions and outcomes according to their importance to clinicians and patients. The panel used the GRADE approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment.

resultsThe panel agreed on 12 recommendations and outlined future research priorities.

conclusionsThese guidelines make key recommendations regarding prophylaxis for frequent recurrent bleeding, desmopressin trials to determine therapy, use of antiplatelet agents and anticoagulant therapy, target VWF and factor VIII activity levels for major surgery, strategies to reduce bleeding during minor surgery or invasive procedures, management options for heavy menstrual bleeding, management of VWD in the context of neuraxial anesthesia during labor and delivery, and management in the postpartum setting.

Indexed as

Hemophilia AThrombosisVenous Thromboembolismvon Willebrand DiseasesFemaleHemostasisHumans

Identifiers

PMID33570647
PMCPMC7805326
OpenAlexW3120545968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.